Tatva Chintan Pharma stock has dropped
April 27 – Tatva Chintan Pharma stock – Tatva Chintan Pharma Chemicals Limited’s stock dropped more than 10% to an intraday low of Rs 2,250 on the BSE after the business announced its profits for the quarter ending March 2022.
For the first quarter ending March 2022, the company reported a combined net profit of Rs 17.5 crore, down 15% year on year. In the previous financial year, it made a consolidated net profit of Rs 21 crore.
In the first quarter, revenue from operations fell to Rs 98.5 crore, compared to Rs 108.6 crore in the same period previous year.
Mr. Chintan Shah, Managing Director, commented on the fiscal year FY22, saying, “For the first time, we surpassed the revenue mark of Rs 4,000 million, we surpassed a PBT of more than Rs 1,000 million, and our export revenue surpassed the mark of Rs 3,000 million for the first time, in fact, our export revenue in FY22 surpassed the total revenue in FY21. Last but not least, becoming listed on the Indian Stock Exchange was a wonderful experience.”
“We are glad to inform you that on the ‘together for sustainability’ platform, we have increased our Audit score from 54% to 87%,” he added.
Read more Private Sector News on India Frontline.